Cargando…

Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma

Biliary tract carcinomas (BTC) are malignant tumors with limited therapeutic options. Clinical experiences with anti-EGFR therapies have produced unsatisfactory results. The strategies of combined inhibition of EGFR and MEK1/2 could be a promising therapeutic option in BTC treatment. Preclinical act...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cavalloni, Giuliana, Peraldo-Neia, Caterina, Varamo, Chiara, Chiorino, Giovanna, Sassi, Francesco, Aglietta, Massimo, Leone, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239557/ https://www.ncbi.nlm.nih.gov/pubmed/27429047 http://dx.doi.org/10.18632/oncotarget.10587

Ejemplares similares

Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation
por: Cavalloni, Giuliana, et al.
Publicado: (2016)

Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas
por: Pignochino, Ymera, et al.
Publicado: (2010)

Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient
por: Cavalloni, Giuliana, et al.
Publicado: (2015)

Gene and microRNA modulation upon trabectedin treatment in a human intrahepatic cholangiocarcinoma paired patient derived xenograft and cell line
por: Peraldo Neia, Caterina, et al.
Publicado: (2016)

Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models
por: Peraldo-Neia, Caterina, et al.
Publicado: (2014)

Paclitaxel Restores Sensitivity to Chemotherapy in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma
por: Massa, Annamaria, et al.
Publicado: (2022)

Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine
por: Varamo, Chiara, et al.
Publicado: (2019)

Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer
por: Peraldo-Neia, Caterina, et al.
Publicado: (2011)

Evolution of the Experimental Models of Cholangiocarcinoma
por: Massa, Annamaria, et al.
Publicado: (2020)

Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR
por: Peraldo-Neia, Caterina, et al.
Publicado: (2018)

Assessment of a High Sensitivity Method for Identification of IDH1 R132x Mutations in Tumors and Plasma of Intrahepatic Cholangiocarcinoma Patients
por: Peraldo-Neia, Caterina, et al.
Publicado: (2019)

A Novel Multidrug-Resistant Cell Line from an Italian Intrahepatic Cholangiocarcinoma Patient
por: Peraldo-Neia, Caterina, et al.
Publicado: (2021)

Proteomic analysis identifies deregulated metabolic and oxidative-associated proteins in Italian intrahepatic cholangiocarcinoma patients
por: Cavalloni, Giuliana, et al.
Publicado: (2021)

Fluoropyrimidine-induced cardiotoxicity in colorectal cancer patients: a prospective observational trial (CHECKPOINT)
por: Lombardi, Pasquale, et al.
Publicado: (2022)

Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma
por: Peraldo-Neia, C., et al.
Publicado: (2018)

Gene Expression Signature Predictive of Neuroendocrine Transformation in Prostate Adenocarcinoma
por: Ostano, Paola, et al.
Publicado: (2020)

Two Novel Ceramide-Like Molecules and miR-5100 Levels as Biomarkers Improve Prediction of Prostate Cancer in Gray-Zone PSA
por: Mello-Grand, Maurizia, et al.
Publicado: (2021)

Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models
por: Del Curatolo, Anais, et al.
Publicado: (2018)

Characterisation of the immune-related transcriptome in resected biliary tract cancers
por: Ghidini, Michele, et al.
Publicado: (2017)

Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways
por: Pignochino, Ymera, et al.
Publicado: (2009)

Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor
por: Liu, Yahong, et al.
Publicado: (2023)

Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity
por: Mittica, Gloria, et al.
Publicado: (2017)

The protease‐inhibitor SerpinB3 as a critical modulator of the stem‐like subset in human cholangiocarcinoma
por: Correnti, Margherita, et al.
Publicado: (2021)

Cellular Immunotherapy Targeting Cancer Stem Cells: Preclinical Evidence and Clinical Perspective
por: Donini, Chiara, et al.
Publicado: (2021)

Establishment of various biliary tract carcinoma cell lines and xenograft models for appropriate preclinical studies
por: Ojima, Hidenori, et al.
Publicado: (2016)

PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models
por: Pignochino, Ymera, et al.
Publicado: (2017)

Whole-exome tumor sequencing study in biliary cancer patients with a response to MEK inhibitors
por: Ahn, Daniel H., et al.
Publicado: (2015)

BILIARY TRACT DISORDERS
Publicado: (1984)

Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer
por: Fornaro, L, et al.
Publicado: (2014)

In Vitro and In Vivo Efficacies of the EGFR/MEK/ERK Signaling Inhibitors in the Treatment of Alveolar Echinococcosis
por: Cheng, Zhe, et al.
Publicado: (2020)

A New Quantitative Classification of the Extrahepatic Biliary Tract Related to Cystic Duct Implantation
por: Renzulli, Matteo, et al.
Publicado: (2020)

Preoperative biliary drainage for biliary tract and ampullary carcinomas
por: Nagino, Masato, et al.
Publicado: (2008)

Dysbiosis of the Fecal and Biliary Microbiota in Biliary Tract Cancer
por: Ito, Zensho, et al.
Publicado: (2022)

EGFR Target Therapy Combined with Gemox for Advanced Biliary Tract Cancers: a Meta-analysis based on RCTs
por: Cai, Wen, et al.
Publicado: (2018)

Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study
por: Kim, Jin Won, et al.
Publicado: (2019)

Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model
por: Dong, Mingjie, et al.
Publicado: (2018)

Neoadjuvant treatment of biliary tract cancer: state-of-the-art and new perspectives
por: Imperatori, Marco, et al.
Publicado: (2016)

PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
por: Ricci, Angela Dalia, et al.
Publicado: (2020)

Diseases of the liver and biliary tract /
Publicado: (1992)

Viral Infections of the Biliary Tract
por: Gupta, Ekta, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_4cnm6p174fntfqta37ckqf7h8t